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The National Health Service (NHS) has committed to
meeting the targets of the Climate Change Act 2008,
which entails reducing its carbon footprint by 80% by
2050. As it stands, the carbon footprint for NHS England is
around 25 million of CO2e (carbon dioxide equivalent), of
which mental health services account for about 6%.1
Therefore, between now and 2050 the necessary carbon
reductions are in the order of 20 million tonnes of CO2e,
of which about 1.2 million tonnes will need to come
from mental health services (assuming reductions occur
proportionally).2 Meeting these carbon reduction targets
will require a transformation in the way mental healthcare
is delivered,3 as the main component of the carbon footprint
of healthcare is not its buildings or energy use (only 17%),
but factors relating to clinical practice. The single largest
component of this for mental healthcare is pharmaceuticals.2
One way of reducing greenhouse gas emissions without
compromising the quality of care is to eliminate inefﬁciencies
in service provision.4 In this paper we explore one potential
area for improvement - the overprescribing of long-acting
injections for the treatment of mental illness. More
speciﬁcally, we assess the prescribing patterns of injections
of ﬂupentixol decanoate for the treatment of schizophrenia
and identify areas of wastage.
We chose ﬂupentixol because it is the most commonly
administered long-acting injection in the UK at 15 000
items per year.5 Furthermore, there is evidence that it is
being prescribed at higher doses and more frequently than
studies suggest is beneﬁcial. The average prescription in the
UK is 60mg every 2 weeks6 and the licensed dose limit is
400mg per week, but a Cochrane review (based on two
small studies) found no evidence for clinical improvement
from doses higher than 50mg every 4 weeks.7 Admittedly,
randomised controlled trials are poorly representative of
naturalistic samples, but a more recent study systematically
reviewed eight studies, again with small numbers and
signiﬁcant heterogeneity, and came to the same conclusions
about dose.8 Despite the small evidence base, evidence
suggests there is a maximum clinically effective dose that is
considerably less than the average prescribed dose.8
We used data from Oxford Health NHS Foundation
Trust and extrapolated to the national level to quantify the
potential economic and environmental impact to the NHS
of prescribing ﬂupentixol decanoate at higher doses and
higher frequency than is clinically beneﬁcial.
Method
We collated the prescription details of all patients receiving
ﬂupentixol decanoate at Oxford Health NHS Foundation
trust in December 2013. The month was chosen at random
and, given the long-term nature of these prescriptions, there
is no reason to expect it to differ from other months.
Included in the data was information about the
medication prescribed, the materials used to administer it
(syringe, needle, glass vial and packaging), the number of
appointments and travel to and from the appointment for
both patients and staff. Travel data were not from the same
patients, but were obtained from a survey conducted
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Aims and method This study explores the economic cost and carbon footprint
associated with current patterns of prescribing long-term ﬂupentixol decanoate long-
acting injections. We conducted an analysis of prescription data from a mental health
trust followed by economic and carbon cost projections using local and national data.
Results A reduction of £300000 could be achieved across England by improving
prescribing behaviour, which equates to £250 per patient per year and 170000 kg
CO2e. These savings are unlikely to be released as cash from the service, but will lead
to higher-value service provision at the same or lower cost. Most of these carbon
emissions are attributable to the carbon footprint of the appointment - 88000 kg
CO2e (including energy use and materials used) and the overprescribing of
medication - 66000 kg CO2e.
Clinical implications Psychiatrists need to review their prescribing practice of long-
acting injections to reduce their impact on the National Health Service ﬁnancial
budget and the environment.
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independently by the Trust during the same period that
included 100 rural and 100 urban patients (details available
from the authors on request). No information was available
on cleaning materials and wasted medication so we have
assumed that neither makes a meaningful contribution to
overall resource use. The ﬁnancial cost of heating and
lighting the clinic roomswere also excluded due to lack of data.
Conversion factors used to estimate the carbon
footprint associated with the materials are presented in
Table 1 and come from either the Department for
Environment, Food & Rural Affairs or the NHS Sustainable
Development Unit. In order not to overestimate the impact,
we assumed the use of recycled materials, although this is
probably a conservative assumption. We assumed that an
injection was administered using a standard NHS 5mL,
21G-VanishPoint intramuscular needle and syringe and a
1mL vial. For transport, we assumed small to average-size
cars. For the ﬁnancial costs of medication, the cheapest
available estimates were used as derived from the British
National Formulary 67 (BNF; www.bnf.org). The costs of
needles and syringes were from the NHS supply chain data
(www.supplychain.nhs.uk) and the cost of appointments
from national databases.9 The administration of an injection
was assumed to require a 15-minute out-patient appoint-
ment with a band 5 nurse and the costs included all
overheads.
We made two assumptions in calculating the costs and
carbon footprints. First, if ﬂupentixol decanoate was
prescribed, it was assumed to be administered and second,
the national average interval was assumed to be the same as
that found for Oxford Health NHS Foundation Trust, and
not the national average of 2 weeks. The latter again entails
a conservative estimate of the economic and environmental
costs. For the national cost of ﬂupentixol, we used actual
national data; all other costs were extrapolated from Oxford
data.
We calculated the economic and environmental savings
that would occur if all patients were given ﬂupentixol
decanoate injections according to best practice, that is
50mg every 4 weeks. We did this by identifying the
resources used to administer one injection; this involved
measuring all resources used and then attaching a ﬁnancial
and environmental cost to the resources, as explained
earlier. Annual costs per organisation were calculated
presuming that each organisation had the same number of
patients on long-term ﬂupentixol decanoate injection, as
was the case for Oxford Health NHS Foundation Trust.
National costs were calculated based on national data that
15 000 prescriptions of ﬂupentixol decanoate were issued at
a cost of £210 000 per year.5
Results
Organisation-level analysis
During December 2013, 28 patients attended 59 appoint-
ments for ﬂupentixol decanoate injection at Oxford Health
NHS Foundation Trust. The average interval was found to
be 2.2 weeks, which is longer than the national average of 2
weeks. The average dose was lower than the national
average: 46mg per week (101mg per injection) v. 60mg
per week.6 There was considerable variation in both
prescribing interval and dose for patients. Prescribing
intervals ranged from 1 to 4 weeks and the dose ranged
from 40mg to 300mg per week. The annual cost of
providing ﬂupentixol decanoate to 28 patients at the Trust
was £18 012 and its annual carbon footprint was 11 519 kg
CO2e (Table 2).
Extrapolation to the national level
In estimating national costs, all ﬁgures remained the same
and were scaled up to the national level except for the
cost of medication, which was given as £210 000 spent
on ﬂupentixol decanoate injection per year for 15 000
prescription items.5 This is costing the NHS in England
around £530 000 per year. Over 50% of these costs are due
to the cost of staff in the appointment at £285 000, followed
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Table 1 Data used in analysis, obtained from other sources
Data Source Amount/unit
Carbon footprint of travel Trust travel surveya 1.87 kg CO2e/appt
Cost of travel Trust travel surveya £2.12/appt
Cost of needle and syringe NHS supply chain 20139 £0.24/appt
Carbon footprint of needle and syringe DEFRA conversion factors (kg CO2e/tonne)
13 0.0162 kg CO2e/appt
b
Carbon footprint of energy use in appointment Sustainable Development Unit 20132 13 kg CO2e/appt
Cost of appointment Unit Costs of Health and Social Care 20139 £19/15min appt with band 5 nursec
Carbon footprint of medications per £1 spent Sustainable Development Unit 20132 0.43 kg CO2e/£
Cost of FD injection British National Formulary 2013 0.0625£/mg
National cost of FD injection prescriptions NHS Business Services Authority 20095 £210000/year in England
National number of FD injection prescriptions NHS Business Services Authority 20095 15 000 prescriptions/year in England
Maximum effective dose of FD Cochrane review7 50mg/4 weeks
appt, appointment; DEFRA, Department for Environment, Food & Rural Affairs; FD, ﬂupentixol decanoate; kg CO2e, kilograms carbon dioxide equivalent; NHS, National
Health Service.
a. Travel survey at Oxford Health NHS Foundation Trust, December 2013. Data available from the authors on request.
b. Calculated as a sum of needle production factor (1222.0), syringe production factor (2.138.0), paper packaging production factor (954.5), glass vial production factor
(508.0) and waste factor for each material if recycled (21).
c. Including all overheads, administrative support, buildings, etc.
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by medication at £210 000. The carbon footprint of this
service amounts to over 314000 kg CO2e across England,
which is mostly attributable to the energy required for the
appointment (195 000 kg CO2e) and medication (90 300 kg
CO2e). The economic and environmental costs of materials
used for the injection are minimal. The costs of travel are
not large but remain noteworthy at around £31 800 and
28 000 kg CO2e per year for England (Table 3).
Analysis of trust-level and national-level data reveals
that the dominant ﬁnancial cost and carbon burden are
associated with the appointment. Medication is ranked in
second place, whereas medical consumables and travel are
less signiﬁcant costs and burdens. At a national level,
medication contributes a larger proportion; this is because
the cheapest BNF cost was used when analysing the Trust
data.
Potential savings associated with evidence-based
administration
Considerable environmental savings could be achieved
across England by changing prescribing behaviour to
adhere to best practice.6,7 Analysis suggests that around
166000 kg CO2e could be saved, most of which is
attributable to the carbon footprint of the energy used in
the appointment (88 000 kg CO2e) and the potential over-
prescribing of medication (66 000 kg CO2e) (Table 4). This
equates to a saving of 168 kg CO2e per patient per year.
Considerable ﬁnancial savings could also be achieved
by changing prescribing practices. The calculations suggest
that around £297 000 could be saved across England by
improving prescribing behaviour, which equates to £250 per
patient per year (Table 4).
Discussion
This paper demonstrates that appropriate dosing of
ﬂupentixol decanoate would have economic and environ-
mental beneﬁts for the NHS. If all prescriptions across
England were given at the maximum 4-week interval and at
no more than the evidence-based maximal effective dose,
around £300000 could theoretically be saved. This change
in prescribing practice would also lead to saving around
166 000 kg CO2e across England per year. This potential
overprescription of ﬂupentixol decanoate injection has the
effect of increasing a patient’s annual carbon footprint by
about 170 kg CO2e over and above that necessary (Table 4),
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Table 2 Economic and environmental costs of ﬂupentixol decanoate per year for Oxford Health NHS Foundation Trust
Resource
Financial cost
»
Financial cost burden
%
Carbon footprint
kg CO2e
Carbon cost burden
%
Medication 3876 22 1668 14
Needle and syringe 156 1 11 51
Appointment 12 576 70 8604 75
Travel 1404 8 1236 11
Total 18 012 100 11 519 100
Table 3 Projected economic and environmental costs of ﬂupentixol decanoate per year for England
Resource
Financial cost
»
Financial cost burden
%
Carbon footprint
kg CO2e
Carbon cost burden
%
Medication 210 000 40 90 300 29
Needle and syringe 3624 1 244 51
Appointment 285 000 54 195 000 62
Travel 31 800 6 28 050 9
Total 530 424 100 313 594 100
Table 4 Projected reductions in economic and environmental costs that could be achieved by increasing interval of
injection to maximum 4 weeks and reducing dose to maximal effective dose
Potential financial savings, »/year Potential carbon footprint savings, kg CO2e/year
Resource For each patient Nationally For each patient For England
Medication 22 152 935 10 65 762
Needle and syringe 3 1631 0 110
Appointment 202 128 250 138 87 750
Travel 23 14 310 20 12 623
Total 250 297 126 168 166 245
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which is the equivalent of a 2% increase of the average
carbon footprint per person in the UK (from 7.9 to 8.1
tonnes CO2).
10 These savings also mean that, for this
particular service, they would also go a long way to meeting
the Climate Change Act targets of an 80% reduction in
carbon footprint.
This analysis, although only based on 28 patients, could
be generalised to other settings. Rural settings would have
an increased proportion of costs associated with travel,
whereas prescribing practices are likely to vary across
regions, as are team and individual management plans for
patients on ﬂupentixol decanoate. Furthermore, some
mental health trusts have renewable energy sources on
site that might considerably reduce the carbon footprint
associated with building energy use.
Some of these savings may not materialise in reality, as
staff time and resources are likely to be used for other
patients. Furthermore, the energy used to heat and light the
building is unlikely to reduce much by reducing appoint-
ment frequency, as the clinical facility is likely to have other
uses. It is, however, an important principle to reduce use of
unnecessary resources as it can enable potential savings to
be used more effectively elsewhere.11 This process creates a
higher-value healthcare system where resources such as
funding, carbon and staff time are released from some parts
of the system to develop new services or support struggling
services.
There are two main issues that lead to unnecessary
ﬁnancial expenditure and emissions of carbon dioxide. The
ﬁrst is the prescribing of medication at doses higher than
evidence suggests is beneﬁcial and the second is the
administration of the injection at shorter intervals than is
necessary.12 Current trends of overprescribing may be
attributable to prescribing habits, personal experience or a
result of the historical use of higher doses. Overprescribing
may also be due to a notable clinical beneﬁt at higher doses
in some individuals.
An important ﬁnding here is that appointments appear
to be a major component of the carbon footprint for mental
health services. If these could be reduced, without
compromising care, major savings could occur. In this
study, increased appointments are driven by the shorter
intervals between doses. Reasons for this might include
convenience, efﬁcacy and the view that some patients
deteriorate in the days before the next dose is due, although
this is not supported by evidence.6 Patients are often
initially prescribed injections at 2-weekly intervals, but
perhaps this interval is not reviewed at subsequent
appointments leading to unnecessary use of appointments
and environmental resources. However, some patients are
administered injections every 2 weeks because it is clinically
necessary to maintain a 2-weekly clinical review and it
is considered logical that the injections should be
administered at the same time. If these patients are also
prescribed within the evidence-based dose, then the savings
associated with medication cannot be included in this
analysis; neither can the savings attributed to the travel. In
such cases, the potential savings associated with increasing
the interval of the injection are due to the increased length
of time needed during each appointment to administer the
injection and the material costs of the needle and syringe.
In this particular instance, based on reviewing the
percentage burden from each component in the analysis,
the savings associated with the increased time for each
appointment are likely to be important but the material use
will not be (less than 1% of total burden). Thus, if the
appointment did not increase in its duration, then there
would be no incentive to increase the interval of the
injection to 4 weeks.
Current prescribing practices can have a detrimental
impact across the three components of sustainability:
environmental, economic and social. The environmental
and economic costs have been outlined, however, the social
costs may also be substantial, including increased frequency
of painful injections, time spent by the patient attending
unnecessary appointments, and an increased risk of
extrapyramidal side-effects.6 The wider social cost of these
side-effects is also likely to be negative and may include
reduced socialisation, reduced employment and larger
healthcare costs, which in turn will increase the carbon
burden and ﬁnancial cost associated.
More evidence is needed to more clearly establish the
maximally effective dose of ﬂupentixol decanoate as the
implications of changing prescribing behaviours can be
substantial for the patients affected. However, if current
practice does not follow the current available evidence, will
additional economic and environmental savings make any
impact on doctors’ behaviours? Perhaps a culture change at
all levels is required to recognise the importance of reducing
wasteful practice and to develop a sense of stewardship over
the use of clinical resources.
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